Unresectable Hepatocellular Carcinoma Clinical Trials

90 clinical trials for Unresectable Hepatocellular Carcinoma across international registries, including 21 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer — RECRUITING · PHASE2
• Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. — RECRUITING · PHASE1
• Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer — RECRUITING · PHASE1
• First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE) — RECRUITING
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma — RECRUITING · PHASE3
• A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma — RECRUITING · PHASE1
• Atezolizumab+Bevacizumab+SBRT in Unresectable HCC — RECRUITING · PHASE1
• Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma — RECRUITING · NA
• MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. — RECRUITING · PHASE1
• Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study — RECRUITING · NA
• The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study — RECRUITING
• Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension — RECRUITING
• Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma — RECRUITING · PHASE1
• A PHASE II STUDY OF STRIDE (DURVALUMAB + TREMELIMUMAB) WITH LENVATINIB VERSUS STRIDE ALONE IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (STRIDE-HCC) — RECRUITING · PHASE2
• SIRT Versus cTACE for Unresectable HCC (CHANCE2506) — RECRUITING · NA
• Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma — RECRUITING
• Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry) — RECRUITING
• TACE With Thermosensitive Nanogel Versus Embosphere for HCC — RECRUITING · NA
• Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC — RECRUITING · PHASE2
• Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC — RECRUITING · PHASE2
• Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma — TERMINATED · PHASE2
• A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab — TERMINATED · PHASE2
• Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver — ACTIVE_NOT_RECRUITING · PHASE2
• Fecal Microbiota Transplantation to RESCUE patients with unresectable Hcc progressors to first line therapy with AtezolizUmaB and Bevacizumab (RESCUE-HUB) — TERMINATED · PHASE2
• BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer — TERMINATED · PHASE1
• AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma — NOT_YET_RECRUITING · NA
• An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery — ACTIVE_NOT_RECRUITING
• Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma — NOT_YET_RECRUITING · NA
• Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer — COMPLETED · PHASE3
• A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma — COMPLETED · PHASE2
• Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma — WITHDRAWN · PHASE2
• Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere — ACTIVE_NOT_RECRUITING · PHASE3
• Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study — COMPLETED
• A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS SORAFENIB OR LENVATINIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB — TERMINATED · PHASE3
• Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) — ACTIVE_NOT_RECRUITING · NA
• Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC — NOT_YET_RECRUITING · NA
• A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab — ACTIVE_NOT_RECRUITING · PHASE3
• Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells — ACTIVE_NOT_RECRUITING · PHASE1
• Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant — TERMINATED · PHASE2
• Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE2
• 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer — COMPLETED · PHASE2
• Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma — COMPLETED · PHASE1
• Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients — ACTIVE_NOT_RECRUITING · NA
• Using Machine Learning to Identify Responders to TACE or HAIC for uHCC — COMPLETED
• FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE2
• A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE2

Refine this search